The American health authorities suspended the sales license of a vaccine against the virus of the ChikunguñaIxchiq, after reports that it has caused “serious adverse effects,” the drug manufacturer announced on Monday.
Ixchiq is one of the only two vaccines approved by the US Food and Medicines Administration (FDA) against the virus transmitted by mosquitoes, which is endemic in the tropical and subtropical regions of the world.
Newsletter return to the world
French pharmaceuticals Valneva obtained the approval of the FDA for the vaccine in 2023, but reports on side effects caused license reviews, also from the European Medicines Agency, in particular on its use in older patients.
You can see: No needle: Bill Gates drives a patch -shaped vaccine that applies to the skin
“The suspension of the license is immediately effective,” Valneva announced regarding the order of the FDA issued on Friday, citing four additional cases of serious side effects, three of whom involved people between 70 and 82 years.
“While we determine the possible next steps, and since the clear threat of Chikunguña continues to increase globally, Valneva remains completely committed to maintaining access to our vaccine as a global health tool,” said the company’s executive director, Thomas Lingelbach.
The pharmacist added that it was evaluating the financial impact of the suspension.
Anti -descent paint in houses exterminates the mosquito of dengue, zika and chikunguña
Public health experts say that Chikunguña represents a potential future pandemic threat as climate change pushes mosquitoes that transmit it to new regions.
This year Europe has registered 27 outbreaks of Chikunguñaa new record for the continent, according to data from the European Center for Disease Prevention and Control (ECDC).
Chikunguña is rarely deadly, although there is a higher risk of death for babies and elderly.
